结节性淋巴细胞为主型霍奇金淋巴瘤中瘤内与外周血TIGIT和PD-1作为免疫生物标志物
研究采用整合多组学分析比较结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)与经典型霍奇金淋巴瘤(cHL)的肿瘤微环境和外周血特征。在121例NLPHL和114例cHL患者中发现NLPHL的PD-1和TIGIT基因表达较cHL富集超过2倍,瘤内PD-1+(和/或TIGIT+)CD4+ T细胞及PD-1+CD8+ T细胞显著增加。体外实验显示免疫检查点阻断(ICB)可减少LP和HRS细胞周围玫瑰花结形成,作者认为值得在NLPHL中进一步评估ICB。
要点
- NLPHL较cHL的PD-1和TIGIT基因表达富集超过2倍。
- NLPHL瘤内PD-1+(和/或TIGIT+)CD4+ T细胞及PD-1+CD8+ T细胞较cHL显著增加。
- 体外ICB可减少LP和HRS细胞周围玫瑰花结形成,作者认为值得在NLPHL中进一步评估ICB。
核心结论
- 结果提示值得在NLPHL中进一步评估免疫检查点阻断(ICB)。
研究设计与样本
- 采用整合多组学分析的发现/验证方法,比较121例NLPHL与114例cHL患者的肿瘤微环境和外周血特征。
主要发现
- NLPHL较cHL的PD-1和TIGIT基因表达富集超过2倍。
- 多重成像显示NLPHL较cHL瘤内PD-1+(和/或TIGIT+)CD4+ T细胞及PD-1+CD8+ T细胞蛋白表达显著增加,包括与淋巴细胞为主(LP)细胞和Hodgkin Reed-Sternberg(HRS)细胞形成玫瑰花结的T细胞。
- NLPHL瘤内PD-1+CD4+ T细胞常表达TCF-1,为T细胞对ICB应答增强的标志。
- 两型霍奇金淋巴瘤外周血特征不同,NLPHL较cHL的TH1、TH2和调节性CD4+ T细胞中PD-1+TIGIT+水平更高,循环PD-1+CD4+细胞高表达TCF-1。
- 两型淋巴瘤血液中高度扩增的克隆性TIGIT+PD-1+CD4+和TIGIT+PD-1+CD8+ T细胞群也存在于肿瘤微环境中,表明表达免疫检查点的T细胞在瘤内与血液间循环。
临床怎么用
- 作者认为值得在NLPHL中进一步评估ICB。
局限性
- 原文结论指出需在NLPHL中进一步评估ICB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In classical Hodgkin lymphoma (cHL), responsiveness to immune-checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is not established. To gain insights into its potential in NLPHL, we compared TME and peripheral blood signatures between HLs using an integrative multiomic analysis. A discovery/validation approach in 121 NLPHL and 114 cHL patients highlighted >2-fold enrichment in programmed cell death-1 (PD-1) and T-cell Ig and ITIM domain (TIGIT) gene expression for NLPHL versus cHL. Multiplex imaging showed marked increase in intra-tumoral protein expression of PD-1+ (and/or TIGIT+) CD4+ T-cells and PD-1+CD8+ T-cells in NLPHL compared to cHL. This included T-cells that rosetted with lymphocyte predominant (LP) and Hodgkin Reed-Sternberg (HRS) cells. In NLPHL, intra-tumoral PD-1+CD4+ T-cells frequently expressed TCF-1, a marker of heightened T-cell response to ICB. The peripheral blood signatures between HLs were also distinct, with higher levels of PD-1+TIGIT+ in TH1, TH2, and regulatory CD4+ T-cells in NLPHL versus cHL. Circulating PD-1+CD4+ had high levels of TCF-1. Notably, in both lymphomas, highly expanded populations of clonal TIGIT+PD-1+CD4+ and TIGIT+PD-1+CD8+ T-cells in the blood were also present in the TME, indicating that immune-checkpoint expressing T-cells circulated between intra-tumoral and blood compartments. In in vitro assays, ICB was capable of reducing rosette formation around LP and HRS cells, suggesting that disruption of rosetting may be a mechanism of action of ICB in HL. Overall, results indicate that further evaluation of ICB is warranted in NLPHL.
引用
- Gunawardana J, Law SC, Sabdia MB, et al. Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol. 2024. PMID: 39152767. doi:10.1002/ajh.27459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。